Developer docs
API playgroundTry for free, no card

Search company profiles

Nautigen

Full company profile

uuid00q8kcw

Namestring
Nautigen
Legal namestring
Nautigen Marine Biomolecular Exploration, Inc.
Websiteurl
nautigen.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Nautigen Marine Biomolecular Exploration, Inc. is a U.S.-based biotechnology startup founded in 2024 and headquartered in Wilmington, Delaware. The company is developing noninvasive remote sensing and biomolecular technologies to discover novel bioactive molecules in deep-sea ecosystems for pharmaceutical and research applications. Its platform pairs deep-sea sample access (planned via partnerships with mineral exploration operators) with metadata-rich cataloging intended to produce a digital biomolecular dataset structured for drug discovery workflows.

The intended product is a digital catalog of biomolecular data with categorization suitable for AI-driven pharmaceutical pipelines. Nautigen targets two primary segments: pharmaceutical companies seeking novel bioactive compounds for drug development, and academic institutions conducting marine biology and pharmaceutical sciences research. The company plans to monetize primarily through licensing of biomolecular data to these B2B customers, using quote-based, negotiated engagements rather than disclosed standard pricing.

The company is at an early stage with 1-10 employees, no disclosed funding, no disclosed customers, and no commercial revenue. It plans to begin operations within the U.S. Exclusive Economic Zone to avoid international regulatory delays, with the founder (a former Fugro marine geodata specialist) serving as the sole named operator and the driving force behind technology, partnership, and commercialization decisions.

Short descriptiontext

Nautigen is a U.S. biotech startup developing noninvasive remote sensing and biomolecular technologies to discover and catalog novel bioactive molecules from deep-sea ecosystems, primarily licensing biomolecular data to pharmaceutical companies and academic institutions for drug discovery research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
marine biomolecular exploration, deep-sea drug discovery, biomolecular data catalog, pharmaceutical biotechnology, marine natural products
Industry3 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Marine Biotechnology
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biomolecular Data Licensing
TypeData Monetisation
Description

The company aims to monetize its digital catalog of biomolecular data by licensing access to pharmaceutical companies and academic institutions. Revenue would come from providing categorized metadata-enriched biomolecular data for drug discovery and research applications, potentially through subscription or per-query licensing arrangements.

wilmingtonbiz.com
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nautigen develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company builds a digital catalog of structured biomolecular data, enriched with metadata, and plans to license access to pharmaceutical companies and academic institutions for drug discovery and research applications. Sample collection is intended to occur through partnerships with deep-sea mineral exploration firms, with initial operations within the U.S. exclusive economic zone.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Deep-sea exploration could advance AI-driven drug discovery and lead to more affordable pharmaceuticals
Product overview1 text field

Nautigen offers a marine biomolecular exploration platform that develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company operates as a single unified product focused on pharmaceutical and other applications, building a digital catalog of biomolecular data categorized with metadata for pharmaceutical companies and academic institutions.

Product and service2 records
1Nautigen Marine Biomolecular Exploration Platform
CategoryMarine Biotechnology / Biomolecular Discovery
Description

A biotechnology platform that uses noninvasive remote sensing and biomolecular technologies to discover, identify, and catalog novel bioactive marine molecules from deep-sea ecosystems. The platform produces a structured digital catalog of biomolecular data enriched with metadata, intended to be licensed to pharmaceutical companies and academic institutions for drug discovery, marine biology research, and AI-driven pharmaceutical development.

2Deep-Sea Biomolecular Data Catalog
CategoryBiomolecular Data / Data Licensing
Description

A structured, metadata-enriched digital catalog of bioactive marine molecules derived from deep-sea ecosystems, intended to be licensed to pharmaceutical companies and academic institutions. The catalog is designed to support drug discovery pipelines, marine biology research, pharmaceutical sciences, and AI-driven drug discovery workflows through query or subscription access.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AI-native drug discovery company that combines high-throughput biology with proprietary data assets. Relevant because it is a mature example of the data-as-asset, AI-driven drug discovery model Nautigen aspires to.

TypeBroad incumbent
Description

Large biotech platform company that operates a biological data and engineering infrastructure for customer R&D. Comparable as a data/platform-as-a-service biology company serving pharmaceutical customers.

TypeDirect peer
Description

Austrian biotech that develops therapeutics based on marine and natural product compounds. Comparable in that it is a smaller, science-driven company commercializing marine bioactives into the pharmaceutical market.

TypeEmerging player
Description

AI-driven drug discovery company building proprietary datasets to fuel machine learning models for pharmaceutical applications. Comparable in that it is constructing novel biological datasets as a core asset for pharma licensing.

TypeEmerging player
Description

Scientific informatics and data management platform for life sciences R&D. Comparable as a software/data platform that aggregates and structures biological data for pharma researchers.

6Kalyagen
TypeEmerging player
Description

Biotech focused on natural product-derived biologics and stem cell therapies. Comparable as a smaller, emerging natural-product biotech exploring novel source organisms for therapeutic development.

TypeDirect peer
Description

Norwegian company that harvests marine organisms (krill) from deep, cold waters for nutraceutical, pharmaceutical, and aquaculture applications. Highly relevant because it demonstrates the deep-sea-to-pharma commercial model Nautigen is attempting to enter.

TypeBroad incumbent
Description

Cloud-based R&D platform for life sciences that manages scientific data and workflows for biotech and pharma customers. Adjacent comparable as a B2B data platform serving the same customer base.

TypeBroad incumbent
Description

Computational chemistry and AI-driven drug discovery platform that licenses software and molecular data to pharmaceutical companies. Comparable as an established incumbent in the AI/biomolecular data licensing category Nautigen is targeting.

TypeDirect peer
Description

Spanish pharmaceutical company that develops marine-derived anticancer drugs (e.g., trabectedin, plitidepsin). Direct competitor because it commercializes bioactive molecules isolated from marine organisms for the same pharmaceutical customers Nautigen targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nautigen

Marine Biotechnologynautigen.com

Nautigen is a U.S. biotech startup developing noninvasive remote sensing and biomolecular technologies to discover and catalog novel bioactive molecules from deep-sea ecosystems, primarily licensing biomolecular data to pharmaceutical companies and academic institutions for drug discovery research.

What Nautigen does

Nautigen Marine Biomolecular Exploration, Inc. is a U.S.-based biotechnology startup founded in 2024 and headquartered in Wilmington, Delaware. The company is developing noninvasive remote sensing and biomolecular technologies to discover novel bioactive molecules in deep-sea ecosystems for pharmaceutical and research applications. Its platform pairs deep-sea sample access (planned via partnerships with mineral exploration operators) with metadata-rich cataloging intended to produce a digital biomolecular dataset structured for drug discovery workflows.

The intended product is a digital catalog of biomolecular data with categorization suitable for AI-driven pharmaceutical pipelines. Nautigen targets two primary segments: pharmaceutical companies seeking novel bioactive compounds for drug development, and academic institutions conducting marine biology and pharmaceutical sciences research. The company plans to monetize primarily through licensing of biomolecular data to these B2B customers, using quote-based, negotiated engagements rather than disclosed standard pricing.

The company is at an early stage with 1-10 employees, no disclosed funding, no disclosed customers, and no commercial revenue. It plans to begin operations within the U.S. Exclusive Economic Zone to avoid international regulatory delays, with the founder (a former Fugro marine geodata specialist) serving as the sole named operator and the driving force behind technology, partnership, and commercialization decisions.

Nautigen firmographics

Firmographics
Name
Nautigen
Legal name
Nautigen Marine Biomolecular Exploration, Inc.
Website
https://nautigen.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Nautigen is a U.S. biotech startup developing noninvasive remote sensing and biomolecular technologies to discover and catalog novel bioactive molecules from deep-sea ecosystems, primarily licensing biomolecular data to pharmaceutical companies and academic institutions for drug discovery research.
Ownership category
akta.pro rank

Nautigen industry classification

Industry
Product category
Marine Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Marine biomolecular exploration
  • Deep-sea drug discovery
  • Biomolecular data catalog
  • Pharmaceutical biotechnology
  • Marine natural products

Where Nautigen is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Markets served

Nautigen business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Biomolecular Data Licensing: The company aims to monetize its digital catalog of biomolecular data by licensing access to pharmaceutical companies and academic institutions. Revenue would come from providing categorized metadata-enriched biomolecular data for drug discovery and research applications, potentially through subscription or per-query licensing arrangements.

Go-to-market motion1 record

Nautigen product offering

Product offering

Core offering

Nautigen develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company builds a digital catalog of structured biomolecular data, enriched with metadata, and plans to license access to pharmaceutical companies and academic institutions for drug discovery and research applications. Sample collection is intended to occur through partnerships with deep-sea mineral exploration firms, with initial operations within the U.S. exclusive economic zone.

Product overview

Nautigen offers a marine biomolecular exploration platform that develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company operates as a single unified product focused on pharmaceutical and other applications, building a digital catalog of biomolecular data categorized with metadata for pharmaceutical companies and academic institutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nautigen Marine Biomolecular Exploration Platform A biotechnology platform that uses noninvasive remote sensing and biomolecular technologies to discover, identify, and catalog novel bioactive marine molecules from deep-sea ecosystems. The platform produces a structured digital catalog of biomolecular data enriched with metadata, intended to be licensed to pharmaceutical companies and academic institutions for drug discovery, marine biology research, and AI-driven pharmaceutical development.
  • Deep-Sea Biomolecular Data Catalog A structured, metadata-enriched digital catalog of bioactive marine molecules derived from deep-sea ecosystems, intended to be licensed to pharmaceutical companies and academic institutions. The catalog is designed to support drug discovery pipelines, marine biology research, pharmaceutical sciences, and AI-driven drug discovery workflows through query or subscription access.

Quantifiable outcome

  • Deep-sea exploration could advance AI-driven drug discovery and lead to more affordable pharmaceuticals

Companies that use Nautigen

Customer profile

Segments2 records

Ideal customer profiles2 records

Nautigen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Nautigen partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Nautigen competitors and assessment

Company assessment

Broad incumbents

  • Recursion Pharmaceuticals: AI-native drug discovery company that combines high-throughput biology with proprietary data assets. Relevant because it is a mature example of the data-as-asset, AI-driven drug discovery model Nautigen aspires to.
  • Ginkgo Bioworks: Large biotech platform company that operates a biological data and engineering infrastructure for customer R&D. Comparable as a data/platform-as-a-service biology company serving pharmaceutical customers.
  • Benchling: Cloud-based R&D platform for life sciences that manages scientific data and workflows for biotech and pharma customers. Adjacent comparable as a B2B data platform serving the same customer base.
  • Schrödinger: Computational chemistry and AI-driven drug discovery platform that licenses software and molecular data to pharmaceutical companies. Comparable as an established incumbent in the AI/biomolecular data licensing category Nautigen is targeting.

Direct peers

  • Marinomed Biotech: Austrian biotech that develops therapeutics based on marine and natural product compounds. Comparable in that it is a smaller, science-driven company commercializing marine bioactives into the pharmaceutical market.
  • Aker BioMarine: Norwegian company that harvests marine organisms (krill) from deep, cold waters for nutraceutical, pharmaceutical, and aquaculture applications. Highly relevant because it demonstrates the deep-sea-to-pharma commercial model Nautigen is attempting to enter.
  • PharmaMar: Spanish pharmaceutical company that develops marine-derived anticancer drugs (e.g., trabectedin, plitidepsin). Direct competitor because it commercializes bioactive molecules isolated from marine organisms for the same pharmaceutical customers Nautigen targets.

Emerging players

  • Insitro: AI-driven drug discovery company building proprietary datasets to fuel machine learning models for pharmaceutical applications. Comparable in that it is constructing novel biological datasets as a core asset for pharma licensing.
  • Dotmatics: Scientific informatics and data management platform for life sciences R&D. Comparable as a software/data platform that aggregates and structures biological data for pharma researchers.
  • Kalyagen: Biotech focused on natural product-derived biologics and stem cell therapies. Comparable as a smaller, emerging natural-product biotech exploring novel source organisms for therapeutic development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Nautigen social profiles

Digital presence

Nautigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nautigen leadership team

Management profile

Number of profiles

Profiles1 record

Nautigen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nautigen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nautigen

What does Nautigen do?

Nautigen develops noninvasive remote sensing and biomolecular technologies to discover novel bioactive marine molecules in deep-sea ecosystems. The company builds a digital catalog of structured biomolecular data, enriched with metadata, and plans to license access to pharmaceutical companies and academic institutions for drug discovery and research applications. Sample collection is intended to occur through partnerships with deep-sea mineral exploration firms, with initial operations within the U.S. exclusive economic zone.

Is Nautigen a public or private company?

Nautigen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nautigen founded?

Nautigen was founded in 2024. It employs 1 to 10 people.

Where is Nautigen based?

Nautigen is headquartered in Wilmington, United States, in the North America region.

How does Nautigen make money?

One revenue line is on record: biomolecular Data Licensing.

Who are Nautigen's main competitors?

Broad incumbents on record are Recursion Pharmaceuticals, Ginkgo Bioworks, Benchling and Schrödinger. Direct peers are Marinomed Biotech, Aker BioMarine and PharmaMar. Emerging players are Insitro, Dotmatics and Kalyagen.

Does Nautigen have an API?

No public API is recorded for Nautigen.

What industry is Nautigen in?

Nautigen's product category is Marine Biotechnology. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals